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Purpose/Objective: The aim of this analysis is to present our 
experience with TRUS-based HDR brachytherapy as a salvage local 
treatment for radio-recurrent prostate cancer. We investigated 
treatment results and toxicity profile of this reirradiation protocol. 
Analysis of clinical and dosimetric parameters was performed to 
define prognostic factors in this group of patients and optimize 
treatment. According to our knowledge this is the largest group of 
patients treated with HDR salvage prostate brachytherapy presented 
in literature.  
Materials and Methods: From August 2001 to November 2008 106 
consecutive patients with recurrent prostate cancer after primary 
irradiation were treated at Department of Brachytherapy in Warsaw, 
Poland. The treatment consisted of HDR interstitial brachytherapy 
based on TRUS images (30Gyin 3 fractions of 10Gy to whole prostate) 
and 12 months of hormonal treatment. The effectiveness of treatment 
was evaluated with Kaplan-Meier estimates for 3- and 5-year overall 
survival (OS) and biochemical progression free survival (bPFS). 
Biochemical recurrence after salvage treatment was defined 
according to ASTRO and Phoenix criteria. The RTOG and CTCAE v. 3.0 
scales were used to grade acute toxicity. Late toxicity was scored 
with RTOG/EORTC scale. We analyzed clinical parameters (Gleason 
score, PSA level, T tumor status), PSA kinetics parameters (PSA 
doubling time, PSA velocity, time to PSA failure) in order to define the 
most suitable group of patients to benefit from this treatment. 
Regression Coxmodel was used to correlated dosimetric parameters 
(Dmax, D10, Dmean, V100) for urethra, rectum and bladder with 
intensity of acute and late toxicity.  
Results: For the purpose of abstract submission we present crude data 
only. With median follow-up of 64 months (range, 20-135) 16 patients 
(15%) died, including 11 (10%) who died of prostate cancer. 43 
patients (48%) are alive with no sign of subsequent biochemical 
progression according to Phoenix criteria. In 15 patients consecutive 
local recurrence was diagnosed. Disease systemic progression was 
observed in 28 patients. The toxicity of treatment is acceptable with 
severe (G3-G4) acute and late GU effects in 8,5% and 5,6% patients, 
respectively. No severe (G3-G4) GI toxicity was reported. Urinary 
incontinence was observed in 21% of patients, being severe (G3-G4 
according to CTCAE scale) in 3,7%. Initial T3 status, short PSADT and 
Gleason score 8-10 on second biopsy are negative prognostic factors 
for OS and bPFS.  
Conclusions: HDR interstitial brachytherapy is effective and safe 
method of treatment in radio-recurrent prostate cancer. At the cost 
of mild to moderate toxicity it gives 50% chance for long-term survival 
without biochemical disease progression. Patients with negative 
prognostic factors (T3 disease, short PSA DT and Gleason score 8-10) 
are not ideal candidates for this treatment.  
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Purpose/Objective: Focal transperineal interstitial permanent 
prostate brachytherapy (BT) aims to reduce the treatment target 
volume to only the primary tumour focus in patients with localized 
prostate cancer. This reduces the required number of seeds and 
needles, lowering the toxicity of the treatment. We investigated the 
geometrical accuracy of implanting a focal treatment plan by 
comparing the planned dose with the delivered dose based on post-
treatment CT dosimetry. 
Materials and Methods: Ten patients with localized prostate cancer 
were treated using 125I BTseeds. Multi-parametric MRI was used to 
delineate the GTV and the GTV expanded by a 5 mm margin to 
account for seed placement variations (GTV+). In the pseudo-focal 
approach, two plans were designed: 1) A focal plan aiming to cover 
only the GTV+, and 2) a plan with those seeds required to cover the 
rest of the prostate. The whole prostate was then treated by applying 
both plans. 
The dose distribution (DD) was reconstructed from seed locations from 
the focal plan using CT images acquired 4 weeks post-treatment. The 
CT images were rigidly registered to T2w MR images acquired the 
same day. These T2w images were also registered to the pre-
treatment MR images (with the GTV delineation) using a non-rigid 
registration to allow for residual prostate swelling and other prostate 
deformations (see overview in figure below).  
The 144 Gy isodose contours (IC) of the planned and delivered DDs 
were compared by measuring the shortest distance from all points on 
one contour to the surface of the other. These distances are negative 
when the planned ICs are smaller than the delivered ICs, and positive 
when the planned ICs are larger. Histograms of the distances between 
the planned and delivered doses are used to determine the margin of 
error for covering the delineated region with the 144 Gy IC. The D90 
and V100 for the GTV and GTV+ of the planned and realized DD were 
determined. 
Results: The GTV+ for the 10 patients enclosed a volume of 5.7 [2.7 – 
13.3] cc (median [min - max]), and the number of BT seeds for the 
focal plan was 18.5 [12 - 27] seeds. The volume for the entire prostate 
was 39.8 [22.5 - 63.3] ml, and it received 68 [44 – 81] seeds. 
The planned vs realized D90 for the GTV+ in all patients was 182 [115 
– 212] Gy vs 130 [66 – 223] Gy.The planned vs realized V100 for the 
GTV+ in all patients was 97.6 [83 - 100] % vs 87 [57 - 100] % of the 
target volume. 95% of the measured distances between the planned 
and delivered 144 Gy IC were smaller than 5.8 mm (see histogram 
below). 
The GTV+ plan, incorporating a 5 mm margin, was sufficient to cover 
the initial GTV (realized D90: 227 [104 - 319] Gy,V100: 100 [76 - 100] 
%). 
 
  
Figure: Imaging and dosimetry volumes, group-averaged histogram of 
distances between planned and delivered 144 Gy isodose contour. 
 
Conclusions: We have shown for this small heterogeneous group of 
patients, that a margin of 0.58 cm is sufficient to achieve adequate 
dose coverage of the planned GTV.  
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Purpose/Objective: In 2003 we examined every indication for 
radiotherapy and how common each indication was. Overall 52% of 
new cases of cancer had an indication for radiotherapy. The 
benchmark was adopted by Australian and UK governments, and by 
the ESTRO QUARTS group. The aim of this study was to develop 
current evidence-based benchmarks for planning radiotherapy service 
provision. 
Materials and Methods: We reviewed national and international 
guidelines for radiotherapy indications in the management of cancers 
notifiable to cancer registries. Benign tumours and non-melanomatous 
skin cancers were excluded because of the lack of population-based 
data. An indication was defined as a clinical situation where 
radiotherapy was the treatment of choice because of superior 
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survival, local control or toxicity profile. Epidemiological data was 
searched to determine the proportion of new cases of cancer with 
each indication. Patient preference data were included for breast and 
prostate cancers. Indications and epidemiological data were reviewed 
by a court of external reviewers. Univariate and Monte Carlo 
simulations were used in sensitivity analysis. 
Results: Over 600 papers and guidelines were reviewed for 20 cancer 
sites. The proportions of cancer types had changed markedly over 10 
years. Prostate cancer increased from 12% of all cancers to 18%. The 
guidelines suggest that 48.6% of new cases of cancer have an 
indication for radiotherapy (with or without chemotherapy) at least 
once in the course of their illness. The range was from 0% for liver 
cancer to 94% for vaginal cancer. 9.1% of cases had an indication for 
synchronous chemoradiotherapy. 
Conclusions: The small decrease in optimum radiotherapy utilisation 
rate was mostly due to changes in the proportions of cancer in the 
population and the removal of a small numberof indications for 
radiotherapy.  
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Purpose/Objective: Documenting key parameters for the activity, 
utilization and infrastructure of radiotherapy in Europe is an impor-
tant part of HERO - the ESTRO Health Economics in Radiation Oncology 
project [1]. HERO has the overall aim to develop a knowledge base of 
the provision of radiotherapy in Europe and build a model for health 
economic evaluation of radiation treatments at the European level. 
The aim of the current report is to describe the initial analysis of a 
pan-European survey of radiotherapy activity and infrastructure. 
Materials and Methods: Contact persons representing the national 
societies within radiation oncology in 42 European countries were 
identified from the ESTRO database and personal contacts. The con-
tact persons were asked to respond to an 84-item web-based ques-
tionnaire detailing epidemiology (population, cancer types and cases 
per year), radiotherapy activity (number of courses, number of pa-
tients treated), infrastructure (departments and technology), staffing 
and economics (public/private facilities, type of reimbursement), all 
on a national level. By December 2012, a total of 29 European coun-
tries have entered their data. 
Results: A large variation between countries was found for most 
parameters studied. Between countries the proportion of annual 
patients treated with radiotherapy relative to all new cancer cases 
varied from 20% to 55% (median 39%); the number of MV machines per 
million inhabitants from 1.25 to 9.62 (median 5.29) and the average 
number of MV machines per department from 0.8 to 8.0 (median 2.0). 
The average number of patients treated per year per MV machine 
varied from 205 to 862 (median 325), per radiation oncologist (89 to 
266; median 167), per radiation physicist (121 to 435; median 263), 
and per radiation therapist (23 to 595; median 101). 
Conclusions: The initial results of this survey have documented an 
enormous heterogeneity, in the order of a factor of 3-5, in all key 
parameters related to activity, utilization, infrastructure and staffing 
of radiotherapy in Europe. Radiotherapy seemed to be underutilized in 
most countries when compared to evidence based data from CCORE 
[2], although there has been a positive evolution in availability and 
infrastructure compared to the earlier studies [3,4]; the European 
average number of MV machines per million inhabitants and per 
department is now in line with QUARTS recommendations [4]. The 
data will be further analyzed in the context of the ESTRO HERO 
project, in collaboration with the national societies and the Interna-
tional Atomic Energy Agency. 
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Purpose/Objective: ESTRO has launched the Health Economics in 
Radiation Oncology (HERO) project to develop a knowledge base and a 
model for health economic evaluation of radiotherapy (1). In this 
framework, the need for radiotherapy will be assessed in order to 
explore the optimum radiotherapy utilization in Europe. The percen-
tage of new cancer patients who require radiotherapy relative to the 
total number of cancer patients (Attributable Radiotherapy Percen-
tage, ARP) is one of the usual measures for planning purposes of 
radiotherapy equipment and staffing. The objective of this work was 
to assess the variability of ARP according to the differences in propor-
tional incidence and in stage at diagnosis by country in Europe. 
Materials and Methods: Decision trees from the Australian CCORE-
projectwere used to assess the percentage of patients requiring 
evidence-basedradiotherapy (2). The original incidence data were 
substituted with theproportional distribution of cancers in different 
European countries, based onincidence data for 2008 from Globocan 
(www.iarc.fr). Available data on population-based stage at diagnosis 
were used for head and neck, lung, breast, prostate and rectal cancer 
in selected countries, used for exploratory purposes. The analysis was 
carried out with TreeAge software. 
Results: The range of values of ARP among European countries varied 
from 52% to 57% of new cancer cases. Stage at diagnosis also contri-
buted to the variability of ARP estimates with a range from 2% in 
breast cancer to 15% in rectal cancer. Most relevant factors influen-
cing the ranges of values observed were due to the percentage of 
cases diagnosed at earlystage with surgery as the only treatment in 
rectal cancer; and the important variability in the incidence by coun-
try of head and neck cancer and prostate.These estimates were 
evidence based and did not take into account clinical problems such 
as comorbidity that could influence the decision for treatment. Also, 
the number of patients that could require retreatment is not included 
in the estimate. Both factors could modify significantly the final ARP 
percentage of incidence cases for planning radiotherapy in a specific 
country. 
Conclusions: ARP is a useful indicator for assessing the needs for 
radiotherapy; however, national differences in the incidence of 
cancer and stage at diagnosis should be taken into account in order to 
make a more realistic estimate for planning purposes. The range 
observed betweencountries and tumour stages could translate into a 
significant change in the number of facilities required. 
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Purpose/Objective: Delaney et al (2003) estimated that more than 
half of all cancer patients should receive radiotherapy at some point 
during the course of the disease. Actual Radiotherapy Utilization 
(RTU) rates are usually lower than the optimal rates 
Our objectives were: 
